

09/011910

FORM PTO-1390 (Modified)
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

10 PCTUS1/REV02 17FEB 1998
U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

Unassigned

INTERNATIONAL APPLICATION NO.
PCT/IB96/00943INTERNATIONAL FILING DATE
30 August 1996PRIORITY DATE CLAIMED
01 September 1995TITLE OF INVENTION
BINDING PROTEINAPPLICANT(S) FOR DO/EO/US
Sergio ABRIGNANI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. A copy of the International Search Report (PCT/ISA/210).
8. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
9. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. A **FIRST** preliminary amendment.
A SECOND or SUBSEQUENT preliminary amendment.
16. A substitute specification.
17. A change of power of attorney and/or address letter.
18. Other items or information:

U S APPLICATION NO. (IF KNOWN, SEE 37 CFR Unassigned	INTERNATIONAL APPLICATION NO. PCT/IB96/00943	ATTORNEY'S DOCKET NUMBER 0336.001		
19. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :		CALCULATIONS PTO USE ONLY		
Search Report has been prepared by the EPO or JPO \$910.00				
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$700.00				
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$770.00				
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00				
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00				
ENTER APPROPRIATE BASIC FEE AMOUNT =				
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30		\$1,950.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	20 - 20 =	0	x \$22.00	\$0.00
Independent claims	1 - 3 =	0	x \$80.00	\$0.00
Multiple Dependent Claims (check if applicable).		☒	\$260.00	
TOTAL OF ABOVE CALCULATIONS				\$2,210.00
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00
SUBTOTAL				\$2,210.00
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				\$0.00
TOTAL NATIONAL FEE				\$2,210.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00
TOTAL FEES ENCLOSED				\$2,210.00
		Amount to be: refunded	\$	
		charged	\$	

A check in the amount of **\$2,210.00** to cover the above fees is enclosed.

Please charge my Deposit Account No. in the amount of to cover the above fees.
A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment
to Deposit Account No. **03-1664** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Alisa A. Harbin
CHIRON CORPORATION
Intellectual Property - R440
P.O. Box 8097
Emeryville, California 94662-8097


SIGNATURE

Alisa A. Harbin

NAME

33,895

REGISTRATION NUMBER

February 1998

DATE

Binding ProteinField of the Invention

The present invention relates to proteins capable of binding
5 the E2 envelope protein of hepatitis C virus (HCV) and to
processes for production and purification.

The invention also relates to the use of the proteins in
therapy and diagnosis and to pharmaceutical compositions and
10 diagnostic kits for such uses. The invention also relates
to a process for screening putative molecules for
competition with HCV for receptor binding. The invention
also relates to an animal model for HCV infection.

15 Brief Description of the Prior Art

HCV (previously known as Non-A Non-B hepatitis - NANBV) is a
positive sense RNA virus of about 10000 nucleotides with a
single open reading frame encoding a polyprotein of about
20 3000 amino acids. Although the structure of the virus has
been elucidated by recombinant DNA techniques (1, 2), the
virus itself has not been isolated and the functions of the
various viral proteins produced by proteolysis of the
polyprotein have only been inferred by analogy with other
25 similar viruses of similar genomic organisation (3).

The viral proteins are all available in recombinant form,
expressed in a variety of cells and cell types, including
yeast, bacteria, insect and mammalian cells (4,5).

30

Two proteins, named E1 and E2 (corresponding to amino acids
192-383 and 384-750 respectively) have been suggested to be
external proteins of the viral envelope which are
responsible for the binding of virus to target cells (3).

35

HCV research is hindered very considerably by the limited
host range of the virus. The only reliable animal model for

HCV infection is the chimpanzee and it is not possible to propagate HCV in tissue culture.

In our copending International patent application 5 PCT/IB95/00692, we describe a method employing flow cytometry to identify cells carrying the HCV receptor. We have shown that, by labelling cells with recombinant E2 envelope protein, it is possible to sort cells using flow cytometry, isolating those cells capable of specific binding 10 to the E2 and therefore potentially carrying the HCV receptor. Employing this technique, we have identified a protein capable of binding to the E2 envelope protein of HCV which we believe to be the receptor for HCV, thereby enabling overcoming many problems in the art.

15

Summary of the Invention

According to the present invention, there is provided a protein having a molecular weight of about 24kD and capable 20 of specifically binding to a protein of hepatitis C virus, or a functionally equivalent variant or fragment thereof.

It will be understood by the skilled person that molecular weights measured as described below using electrophoresis 25 are inherently subject to interpretation since they are measured relative to standard molecular weight markers. However, in the context of this specification the expression "24kd" is unambiguous when read in context, since only one such protein is obtained by following the processes 30 described below with the defined characteristic of binding to hepatitis C virus.

A significant characterising feature of the protein according to the present invention is its ability to bind 35 specifically to an HCV protein, preferably an envelope protein, particularly the E2 protein.

On the basis of this specificity and other features

described below, we infer that the 24kd protein of the invention is a cellular receptor for HCV.

We have shown that the protein is ubiquitous in humans
5 amongst the cell types we have tested, paralleling the situation found for many other viruses of this type (such as vaccinia virus and influenza virus).

We have shown that the protein is species specific in a
10 manner which matches the species specificity of HCV itself.

Our experiments have shown that the 24kd protein is functionally unglycosylated. Treatment with glycosidases does not affect the ability of the 24kd protein to bind to
15 the E2 protein and does not appear significantly to reduce the molecular weight. We infer therefore that, if the protein is glycosylated at all, glycosylation must be restricted to a small number of sugar moieties and is not necessary for functional activity of the protein.

20

Our experiments have also shown that the protein is a transmembrane protein, again suggesting that it is a cellular receptor.

25 Finally, experiments with cell lines hyperexpressing the protein indicate that such cells are prone to aggregation suggesting that the protein may be an adhesion molecule of some form.

30 The 24kd protein may be in its naturally occurring form, albeit isolated from its native environment, or may be modified, provided that it retains the functional characteristic of at least binding to the E2 protein of HCV. For example, the 24 kd protein may be modified chemically to
35 introduce one or more chemical modifications to the amino acid structure. It may include modifications of the amino acid sequence involving one or more insertions, deletions or replaced amino acids. It may, for example, be truncated by

the removal of a functional part of the transmembrane domain to facilitate ready production by recombinant DNA means in a suitable mammalian host cell (6).

5 The protein of the present invention may be purified from cells exhibiting binding to an HCV protein, such as the E2 protein.

According to the present invention there is provided a
10 process for the preparation of a protein according to the invention or a functionally equivalent variant or fragment thereof comprising the step of culturing cells exhibiting binding to an HCV protein and purifying from a cell preparation a protein according to the invention.

15

The cells may be transformed or untransformed mammalian cells and are suitably human cells.

20 The cells may be screened for binding to an HCV protein using fluorescence flow cytometry or any other suitable assay. For example, the present description provides the information necessary to produce the 24kd protein or a functionally equivalent variant or fragment thereof which then itself be used to assay for further cells carrying the
25 protein.

The cell preparation may be a cell membrane preparation but is preferably a plasma cell membrane preparation.

30 Preferably the cells are selected and cloned to provide hyperexpression of the protein of the present invention.

We have discovered that the protein is precipitated by ammonium sulphate at between 33 and 50% of saturation.

35

Preferably, therefore, the cell preparation is subjected to an ammonium sulphate precipitation purification step employing ammonium sulphate at between 33 and 50%. Suitably

a first precipitation is conducted at less than 33% and precipitated material discarded followed by precipitation of the desired material at between 33 and 50%, most preferably 50%.

5

Preferably, the purification involves at least one step of hydrophobic interaction chromatography.

We have also discovered that the protein is stable to acetone precipitation, thereby providing a still further characterisation and a useful purification process step.

Most preferably in optimised form, the process of purification comprises the steps of:

15

i) preparing a plasma cell membrane preparation of mammalian cells selected for hyperexpression of the 24kd protein of the invention,

20

ii) subjecting the preparation to ammonium sulphate precipitation at less than 33% saturation and retaining the supernatant,

25

iii) subjecting the supernatant to ammonium sulphate precipitation at between 33 and 50% saturation and retaining the precipitate, and

iv) resuspending the precipitate and subjecting it to hydrophobic interaction chromatography

30

As an alternative to purification from wild-type cell lines, the protein of the invention or a functionally equivalent variant or fragment thereof may be made by any suitable synthetic process including chemical synthesis. Suitably, 35 the protein or a functionally equivalent variant or fragment thereof is made by expression of a gene encoding the protein in a suitable host cell or animal.

According to a further aspect of the invention, there is provided a method for treating an infection of HCV comprising administering to a patient an amount of the protein of the invention or a functionally equivalent variant or fragment thereof effective to reduce the infectivity of the virus.

Since the infection mechanism of HCV appears to depend, in part, upon the availability of a cell surface receptor, making available a soluble form of the protein of the invention will act as an antagonist of binding of HCV to the cellular receptor thus reducing or preventing the infection process and thereby treating the disease.

A suitable soluble form of the protein of the invention might comprise, for example, a truncated form of the protein from which the transmembrane domain has been removed either by a protein cleavage step or ,by design, in a chemical or recombinant DNA synthesis.

Alternatively, a hybrid particle comprising at least one particle-forming protein, such as hepatitis B surface antigen or a particle-forming fragment thereof, in combination with the protein of the invention or a functionally equivalent variant or fragment thereof could be used as an antagonist of binding of HCV to the cellular receptor.

According to a further aspect of the invention, there is provided a pharmaceutical composition comprising a protein of the invention or a functionally equivalent variant or fragment thereof, optionally as a pharmaceutically acceptable salt, in combination with a pharmaceutically acceptable carrier.

The pharmaceutical composition may be in any appropriate form for administration including oral and parenteral compositions.

A process is also provided for making the pharmaceutical composition, in which a protein of the present invention or a functionally equivalent variant or fragment thereof is
5 brought into association with a pharmaceutically acceptable carrier.

According to a further aspect of the invention, there is provided a protein of the invention or a functionally equivalent variant or fragment thereof for use as a
10 pharmaceutical.

According to a further aspect of the invention, there is provided the use of a protein of the invention or a functionally equivalent variant or fragment thereof in the manufacture of a medicament for the treatment of an HCV infection.
15

The ability of a protein of the invention or a functionally equivalent variant or fragment thereof to bind to HCV permits the use of the protein or a functionally equivalent variant or fragment thereof as a diagnostic for HCV infection, for example in an ELISA or RIA.
20

25 A soluble form of the protein could, for example, be used in an ELISA form of assay to measure neutralising antibodies in serum.

According to a further aspect of the invention, there is provided an assay for HCV antibodies in a serum sample comprising the step of allowing competitive binding between antibodies in the sample and a known amount of an HCV protein for binding to a protein of the invention or a functionally equivalent variant or fragment thereof and
30 measuring the amount of the known HCV protein bound.
35

Preferably, the protein of the invention or functionally equivalent variant or fragment thereof is immobilised on a

solid support and the HCV protein, which may suitably be E2 HCV envelope protein, optionally recombinant E2 protein, is labelled, suitably enzyme labelled.

5 In an assay of this form, competitive binding between antibodies and the HCV protein for binding to the protein of the invention results in the bound HCV protein being a measure of antibodies in the serum sample, most particularly, neutralising antibodies in the serum sample.

10

A significant advantage of the assay is that measurement is made of neutralising antibodies directly (i.e those which interfere with binding of HCV envelope protein to the cellular receptor). Such an assay, particularly in the form 15 of an ELISA test has considerable applications in the clinical environment and in routine blood screening.

Also, since the assay measures neutralising antibody titre, the assay forms a ready measure of putative vaccine 20 efficacy, neutralising antibody titre being correlated with host protection.

In a further aspect of the invention, there is provided a diagnostic kit comprising the protein of the invention or a 25 functionally equivalent variant or fragment thereof. Preferably the kit also contains at least one HCV labelled HCV protein, optionally enzyme labelled.

The protein of the invention or a functionally equivalent 30 variant or fragment thereof may be used to screen for chemical compounds mimicking the HCV surface structure responsible for binding to the HCV receptor.

According to a further aspect of the invention, there is 35 provided a method for screening chemical compounds for ability to bind to the region of HCV responsible for binding to a host cell, comprising measuring the binding of a chemical compound to be screened to a protein of the

invention or a functionally equivalent variant or fragment thereof.

This aspect of the invention encompasses the products of the
5 screening process whether alone, in the form of a pharmaceutically acceptable salt, in combination with one or more other active compounds and/or in combination with one or more pharmaceutically acceptable carriers. Processes for making a pharmaceutical composition are also provided in
10 which a chemical compound identified by the process of the invention is brought into association with a pharmaceutically acceptable carrier.

The chemical compound may be an organic chemical and may
15 contain amino acids or amino acid analogues. Preferably however the chemical compound is a polypeptide or a polypeptide which has been chemically modified to alter its specific properties, such as the affinity of binding to the protein of the invention or a functionally equivalent
20 variant or fragment thereof or its stability *in vivo*.

At present, the only available animal model is the chimpanzee, which is a protected species. Experiments on such animals pose a number of difficulties which together
25 result in a very considerable expense (a one year experiment with one chimpanzee can cost \$70,000). Compared to this, a mouse model would be far more acceptable. Unfortunately, as described below the HCV receptor, whilst ubiquitous in humans and found in chimpanzees, is absent in other mammals.
30 A transgenic mammal, for example a mouse, carrying the HCV receptor on the cell surface would be of great benefit to HCV research and the development of vaccines.

According to a further aspect of the invention, there is
35 provided a transgenic non-human mammal, suitably a mouse, carrying a transgene encoding a protein of the invention or a functionally equivalent variant or fragment thereof.

The transgenic animal of the invention may carry one or more other transgenes to assist in maintaining an HCV infection.

There is also provided a process for producing a transgenic
5 animal comprising the step of introducing a DNA encoding a protein of the invention or a functionally equivalent variant or fragment thereof into the embryo of a non-human mammal, preferably a mouse.

10 Brief Description of the Drawings

Figure 1 is a schematic diagram describing an assay in which HCV receptor-binding ligands bind to receptors on HCV receptor target cells and are measured by first binding
15 rabbit anti-HCV antibody and then by binding a labelled anti-rabbit IgG-FITC F(ab') fragment prior to cell separation by FACScan analysis.

Figure 2 is a computer-generated histogram depicting the
20 results of a FACScan analysis of binding of HCV protein to haematopoietic cells (MOLT-4, Jurkat, K562, Daudi, EBV-B) and epithelial cells (Hela, Adenocarcinoma and Huh 7) resulting from binding with HCV proteins (filled curve unlabelled control, open curve labelled). The plot is of
25 cell population against fluorescence intensity.

Figure 3 is a computer-generated histogram depicting the results of a FACScan analysis of purified RA, purified RO, cord blood purif. RA, cord blood RA pha stim., KC3 T-cell
30 clone (TCC) and SAG S9 TCC, which were tested for binding to recombinant HCV E2 protein expressed in CHO cells (filled curve unlabelled control, open curve labelled). The plot is of cell population against fluorescence intensity.

35 Figure 4 is a set of computer-generated histograms depicting the results of a FACScan analysis of the binding of E2 CHO to MOLT-4 cells with and without treatment with beta mercaptoethanol (BSH) an S-S linkage reducing agent (filled

curve unlabelled control, open curve labelled). The plot is of cell population against fluorescence intensity.

Figure 5 is a set of computer-generated histograms depicting 5 the results of a FACScan analysis of the binding of E2 CHO to MOLT-4 cells with and without treatment with Endo-H, a deglycosylating enzyme (filled curve unlabelled control, open curve labelled). The plot is of cell population against fluorescence intensity.

10

Figure 6 is a western-blot of membranes prepared from MOLT-4 cells and solubilized in different buffers (see page 22 for lane descriptions).

15 Figure 7 is a western blot of plasmatic membrane from MOLT-4 cells (see page 23 for lane descriptions).

Figure 8 is a western blot of MOLT-4 and PBMC membrane proteins (see page 23 for lane descriptions).

20

Figure 9 is a western blot of MOLT 4 cells membrane proteins treated with N-Glycosidase F (see page 26 for lane descriptions).

25 Figure 10 is a western Blot of MOLT-4 and COS-7 membranes electrophoresed in reducing and non reducing conditions (see page for 27 lane descriptions).

30 Figure 11 is a western blot of an experiment demonstrating immunoprecipitation of an E2-CHO/putative receptor complex (see page 29 for lane descriptions).

Figure 12 is a western blot of ammonium sulphate fractions from MOLT-4 cells membranes (see page 31 for lanes).

35

Figure 13 is a western blot of samples from a hydrophobic interaction chromatography experiment with an acetone precipitation step (see page 32 for lanes).

Detailed Description of the Invention

The arrangement of the detailed description is as follows:

5

1.	General Description	13
2.	Cellular Assay	13
2.1.	FACS analysis of cells binding to E2	13
2.2.	Effect of E2 modification on binding	15
2.2.1.	E2 reduction	16
2.2.2.	E2 deglycosylation	16
2.3.	Monoclonal antibody production	17
3.	Preparation of 24kd putative receptor	17
3.1.	24kd protein preparation from MOLT-4 cells . .	17
3.1.1.	Membrane purification	17
3.1.2.	Plasma membrane purification	18
3.2.	Hyperexpressing MOLT-4 cells	20
4.	Characterisation of Receptor	20
4.1.	Western blot protocol	20
4.1.1.	Membrane proteins	21
4.1.2.	Plasma membrane proteins	22
4.1.3.	Western blot of PBMC cells	23
4.2.	Cell surface expression of receptor	23
4.3.	Effect of enzymes on 24kd protein binding . . .	24
4.3.1.	Flow cytometry	24
4.3.2.	Western blot on MOLT-4/N-Glycosidase F	26
4.4.	Effect of reducing condition on binding	26
5.	Optimising Purification	27
5.1.	Immunoprecipitation	27
5.2.	Ammonium Sulphate Fractionation	30
5.3.	Hydrophobic Interaction Chromatography	31
5.4.	Acetone precipitation	32
6.	Sequencing and cloning	33

6.1. Amino acid sequence	33
6.2. DNA sequence cloning and sequencing	33

1. General Description

5

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of immunology, cytofluorimetry and molecular biology, which are within the skill of the art. Such techniques are explained fully in
10 the literature (7).

The skilled person will understand and be familiar with the general methods and techniques of assay design and practice. The invention is described herein in sufficient detail for
15 the skilled person to understand and repeat the experiments disclosed.

Standard abbreviations for virus and proteins are used in this specification. All publications, patents and patent
20 applications cited herein are incorporated by reference.

Envelope 1 (E1) and Envelope 2 (E2) of HCV refer to the proteins, and fragments thereof, the nucleotide sequence of which are published (EP-A-0318216 and EP-A-0388232 cited above). The nucleotides of the E1 and E2 genes and of the
25 encoded proteins vary in different HCV isolates. Therefore, the E1 and E2 for any HCV isolates are identified because included in the amino acid sequences 192-383 and 384-750 respectively.

30 E1 and E2 have been produced by recombinant DNA techniques using different expression systems (Spaete et al and Chien et al cited above).

2. Cellular Assay

35

2.1. FACS analysis of cells binding to E2

An experiment was performed with the aim of measuring the

ability of HCV protein to bind to various cell types which should have the putative HCV receptor.

Cells (10^5 /well) from the human T cell lymphoma, Molt-4
5 (commercially available and obtainable from the American Type Culture Collection), were pelleted in 96 U-bottom microplates (Costar) by centrifugation at 200 x g for 5 minutes at 4°C. Twenty microliters of HCV proteins (CHO expressed recombinant E2 protein) diluted in PBS in
10 different concentrations (from 10 µg/ml to 0.001 µg/ml) were mixed with the pellet of Molt-4 cells and incubated at 4°C for 60 minutes. Non bound HCV proteins were removed by two centrifugations in PBS at 200 x g for 5 minutes at 4°C.
15 Cells were subsequently incubated for 30 minutes at 4°C with various dilutions (from 1/10 to 1/300000) of sera from humans, chimps, rabbits or mice that were either infected with HCV or have been immunised with HCV recombinant proteins or the corresponding pre-immune sera as control.
20 The cells were washed twice in PBS and incubated for 30 minutes with the appropriate dilutions of fluorescein-isothiocyanate-conjugated antisera (either to human IgG, or rabbit IgG, or mouse IgG).
25 Cells were subsequently washed in PBS at 4°C, resuspended in 100 µl PBS and cell-bound fluorescence was analyzed with a FCScan flow cytometer (Becton & Dickinson). By using a dot plot display of forward and side scatter, the machine is
30 gated to include viable single cells and to exclude cell debris and clumps of cells. A total of 5000 events were collected and analyses of the data was done by using the Lysis II software program from Becton & Dickinson. This program produces histograms of each cell sample and
35 calculates the mean channel fluorescence of the cell population, which directly relates to the surface density of fluorescently labelled HCV proteins bound to the cells.

Mean fluorescence values (mean channel number) of cells incubated with or without HCV proteins and with immune or preimmune sera were compared. The threshold for positivity is set for each experiment by flow cytometric analysis of 5 cells without HCV proteins bound which have been incubated with antisera to HCV proteins and the FITC labelled second antibody. A representative binding experiment is shown in Figure 1 which shows the separation achieved by flow cytometric analysis.

10

The experiment was also conducted with a variety of cell lines (for example haematopoietic cells other than MOLT-4 such as Jurkat, K562, Daudi, EBV-B (B-cell line transformed with Epstein-Barr virus and epithelial cells such as Hela, 15 Adenocarcinoma and Huh 7) to identify cells capable of binding HCV proteins and therefore cells that have the putative receptor(s) for HCV following the protocol described above. It will be appreciated that repetition of this experiment is not necessary for the working of the 20 present invention, but serves to prove the ubiquitous nature of the putative receptor (most of the cells are, in any event commonly available and were, in fact, obtained from the ATCC). The results were shown in Figure 2, together with those for MOLT-4 and demonstrate that the specific 25 binding of E2 to cells is widespread, suggesting that the HCV receptor is ubiquitous.

In a similar series of experiments, purified RA, purified RO, cord blood purif. RA, cord blood RA pha stim., KC3 TCC 30 and SAG S9 TCC, which were tested for binding to recombinant HCV E2 protein expressed in CHO cells (E2-CHO) and found to bind confirming that binding occurs to non-transformed cell lines. The results are shown in Figure 3.

35 2.2. Effect of E2 modification on binding

The effects of modifying the recombinant HCV protein E2, expressed in CHO cells (E2-CHO) on binding to MOLT-4 cells

were investigated using a reducing agent and a deglycosylating enzyme.

2.2.1. E2 reduction

5

25 μ l of E2-CHO SMC-PC (130 μ g/ml) in 20 mM potassium phosphate, 0.1 M NaCl, pH 6.0 were buffered at pH 8.0 with 1M Tris-base (total 1 μ l) and then added with BSH (beta mercaptoethanol) to a final concentration of 500mM; tubes 10 were flushed with nitrogen and the reaction allowed to proceed for 100 minutes at 37°C.

Samples from above were diluted 1:20 with RPMI medium and used for a FACS binding assay with MOLT-4 cells as described 15 above. The final concentration of BSH in the FACS assay was 12.5 mM and under these conditions, cells were verified to be alive in previous preliminary experiments (over 90% of cells still alive at 50 mM BSH).

20 The results in Figure 4 show that binding of MOLT-4 cells to recombinant E2 is substantially reduced on reduction with beta-mercaptopethanol, indicating a requirement for a correct E2 conformation maintained by S-S bridges.

25 2.2.2. E2 deglycosylation

25 μ l of E2-CHO SMC-PC (130 μ g/ml) in 20 mM potassium phosphate, 0.1 M NaCl, pH 6.0 were added with 30 μ l of 0.2 M NaH₂PO₄ to a final pH of 5.5 plus SDS to a final 30 concentration of 0.01%. Then 10 μ l of Endo-H stock was added to a final concentration of 200 mU/ml keeping the pH constant and the resulting sample was kept at 37°C for 20 hours. The sample was then diluted 1:20 with RPMI and used for in a FACS binding assay as described above.

35

The results in Figure 5 show that binding of MOLT-4 cells to recombinant E2 is substantially reduced on deglycosylation with Endo-H, indicating a requirement for glycosylation of

E2 for binding.

2.3. Monoclonal antibody production

5 Monoclonal antibodies were prepared using standard procedures and by immunising mice with recombinant HCV E2 produced in CHO cells (E2-CHO). Several cell lines were established which were capable of binding to E2-CHO as were cell lines capable of binding to E2 bound to MOLT-4 cells
10 and cell lines capable of neutralising the binding of E2-CHO to MOLT-4 cells.

3. Preparation of 24kd putative receptor

15 3.1. 24kd protein preparation from MOLT-4 cells

The 24kd protein was purified from MOLT-4 cells by membrane purification and by plasma membrane purification, the latter giving the better yield of protein.

20 3.1.1. Membrane purification

MOLT-4 cells were grown at 37°C, 5% CO₂ in RPMI buffered with 25 mM Hepes in a growth medium containing Fetal Calf
25 Serum (FCS - final concentration 5%), 1 mM glutamine, 100 µg/ml kanamycin, MEM vitamins (Gibco), 1mM sodium pyruvate, MEM non essential amino acids (Gibco), 5 x 10⁻⁵M β-mercaptoethanol.

30 Cells were harvested after reaching a density of 750,000 - 1,000,000 cells per ml.

The growth medium containing cells was centrifuged at 300g for 10 minutes to pellet down the cells. Pelleted cells
35 were washed three times in PBS Buffer (resuspended and recentrifuged).

The cell pellet was resuspended in hypotonic solution at 1

ml of hypotonic solution per 100 x 10⁶ cells.

The hypotonic solution contained Tris (10 mM), NaCl (10 mM), CaCl₂ (0.2 mM), MgCl₂ (1.5 mM), PMSF (1.0 mM), aprotinin 5 (2.0 µg/ml), pepstatin (0.7 µg/ml) and leupeptin (0.5 µg/ml).

Cells were left at 4°C under gentle shaking for 20 minutes and then disrupted with 25 strokes of a Potter manual 10 homogenizer.

Membranes were recovered after sequential centrifugation of the supernatant at 100g for 7 minutes, 3500 g for 10 minutes and 40,000 g for 60 minutes. The pellet obtained from the 15 above was dissolved in suitable buffer.

The buffer used for dissolution of the 40,000 g membrane pellet contained 1% Triton X-100 in PBS buffer pH 7.4, 8 mM Chaps in PBS buffer pH 7.4 and 4 M Urea in sodium phosphate 20 buffer pH 7.4.

All the buffers used for membrane solubilisation contained protease inhibitors at the concentrations reported above for the hypotonic solution and were used at a ratio of 200 µl of 25 buffer per 5 x 10⁸ cells.

Solubilised material was centrifuged at 100,000 g for 60 minutes and the supernatant kept for further use after estimation of protein content by BCA method.

30

The material obtained was subjected to analyses as described below.

3.1.2. Plasma membrane purification

35

The procedure for plasma membrane purification was based on Morre' D.J. et al. (8).

MOLT-4 cells were grown at 37°C, 5% CO₂ in RPMI buffered with 25 mM Hepes in a growth medium containing Fetal Calf Serum (FCS - final concentration 5%), 1 mM glutamine, 100 µl/ml kanamycin, MEM vitamins (Gibco), 1mM sodium pyruvate, 5 MEM non essential amino acids (Gibco), 5 x 10⁻⁵ M β-mercaptoethanol.

Cells were pelleted from culture medium and washed three times with PBS.

10

The pelleted cells were resuspended in 0.2 mM EDTA, 1 mM NaHCO₃ containing the following protease inhibitors: PMSF (1.0 mM), aprotinin (2.0 µg/ml), pepstatin (0.7 µg/ml), leupeptin (0.5 µg/ml) at a ratio between buffer and cells of 15 2 ml per each 10⁸ cells.

Resuspended cells were disrupted with a Polytron homogenizer using an S25 N10 G probe for 40 seconds at 9500 rpm. Cell disruption was verified by optical microscope. The 20 homogenate was centrifuged at 300 g and the resulting supernatant further centrifuged at 23,500 g for 60 minutes. The resulting pellet was resuspended in 0.2 M potassium phosphate pH 7.2 containing protease inhibitors in the ratios described above. The buffer volume was 1 ml each 5 25 x 10⁸ cells.

The membrane suspension was partitioned across the following two phase system:

30	20% (w/w) T500 Dextran	13.2g
	40% (w/w) PEG 3350	6.6 g
	0.2 KP, pH 7.2	0.8 ml
	membrane susp.	5.0 g
	Distilled water	up to 35 g

35

The sample was chilled at 4°C and the tubes were inverted 30 to 40 times keeping the temperature constant. The sample was then centrifuged on a swinging bucket rotor at 150-200 g for

5 minutes at 4°C. The upper phase was removed and five-fold diluted with 1mM sodium bicarbonate containing protease inhibitors. The membranes were collected by centrifugation at 30,000 g for 30 minutes.

5

The pellet was dissolved in a suitable buffer and centrifuged at 100,000 g for 60 minutes to eliminate undissolved material.

10 The material obtained was subjected to analyses as described below.

3.2. Hyperexpressing MOLT-4 cells

15 A further cell line capable of hyperexpression of the characteristic binding ability for E2 was prepared by selecting and recloning MOLT-4 cells binding E2 strongly. The resulting cell-line showed a markedly greater binding affinity for E2 than the wild-type strain.

20

4. Characterisation of Receptor

4.1. Western blot protocol

25 The following experiments demonstrate binding of E2 to purified 24kd protein in a western blot of proteins from MOLT-4 cells purified from membranes and from plasma membranes and from peripheral blood mononuclear cells (PBMC).

30

Unless otherwise indicated, all SDS-PAGE experiments were performed according to Laemmli et al (9), samples of solubilised membranes were run under non-reducing conditions and without boiling before each electrophoretic run.

35

After electrophoretic transfer (Western blot) in buffer containing 25 mM Tris, 192 mM glycine, 20% methanol at constant electric field of 10 Volts/cm, blotted transfer

supports were saturated for 2 hours in PBS buffer pH 7.4 containing 0.05% Tween 20 and 10% powdered skimmed milk at room temperature. After 1 x 15 minutes and 2 x 5 minutes, washes in PBS, 0.05% Tween 20 containing 1% powdered skimmed
5 milk, transfer supports were incubated overnight with E2-CHO recombinant protein at a concentration of 1-2 µg/ml dissolved in PBS buffer containing 0.05% Tween 20, 1% milk, 0.02% sodium azide. Negative control transfer supports (blotted with the same samples) were incubated for the same
10 time in the same buffer without E2-CHO protein.

To detect E2-CHO recombinant protein bound to the transfer supports, these were incubated with the culture supernatant of an hybridoma named 291A2 (a monoclonal antibody that
15 recognises epitopes exposed on E2 when bound to its putative receptor) at 1:500 dilution in PBS, Tween 0.05%, milk 1% for 2 hours.

After this step, transfer supports were washed 1 x 15
20 minutes and 2 x 5 minutes with PBS Tween 0.05% milk 1% solution. Transfer supports were then incubated for 1 hour with biotin conjugated goat anti-mouse immunoglobulin specific polyclonal antibody of commercial source (PharMingen, San Diego, CA, USA) at 1:2000 dilution in the
25 PBS/Tween/Milk solution mentioned above. After this step, transfer supports were washed 1 x 15 minutes and 2 x 5 minutes with PBS/Tween/Milk. Finally transfer supports were incubated for 1 hour with Extravidin®-Peroxidase (Sigma Immunochemicals Co., St Louis, MO, USA) at 1:2500 dilution
30 in PBS/Tween/Milk. Transfer supports were then washed 1 x 15 minutes and 4 x 5 minutes with PBS buffer pH 7.4 containing 0.05% Tween 20. Chemiluminescent staining was performed using ECL™ western blotting detection reagents (Amersham, UK).

35

4.1.1. Membrane proteins

A membrane preparation was prepared as described above.

Membrane pellets resulting from 40,000 g centrifugation were dissolved in buffers reported below and centrifuged at 100,000 g to remove undissolved material. Pellets were 5 reextracted with 1% Triton X-100 in PBS pH 7.4.

Following SDS-PAGE (15 μ g/lane) and blotting, the transfer supports were incubated with E2-CHO recombinant protein as described above.

10

The results are shown in Figure 6.

	<u>Lane</u>	<u>Description</u>
	1A	4M Urea in 50 mM sodium phosphate pH 7.2
15	2A	Pellet from lane 1A sample solubilized in 1% Triton X-100 in PBS pH 7.4
	3A	1% Triton X-100 in PBS pH 7.4
	4A	Pellet from lane 3A sample solubilized in 1% Triton X-100 in PBS pH 7.4
20	5A	0.01% Triton X-100 in PBS pH 7.4
	6A	Pellet from lane 5A sample solubilized in 1% Triton X-100 in PBS pH 7.4

1B to 6B are negative controls for the corresponding samples 25 in lanes 1A to 6A.

The protein band at 24kd is clearly visible.

4.1.2. Plasma membrane proteins

30

A plasma membrane preparation was prepared as described above.

Plasma membranes were solubilized in PBS pH 7.4 containing 35 1% Triton X-100 and subjected to Laemmli SDS-PAGE. The transfer support was incubated with E2-CHO recombinant protein.

The results are shown in Figure 7.

<u>Lane</u>	<u>Description</u>
1A	plasma membranes, 10 µg total protein content
5 2A	plasma membranes, 5 µg total protein content

Lanes 1B and 2B are negative controls for the corresponding samples in lanes 1A and 2A.

10 The protein band at 24kd is clearly visible.

4.1.3. Western blot of PBMC cells

To assess whether the 24kd protein could be identified in
15 normal cells a sample of peripheral blood mononuclear cells was purified using the procedure described above and subjected to western blotting as described above.

The results are described in Figure 8.

20

<u>Lane</u>	<u>Description</u>
1/2	Molt-4 membrane proteins
3	PBMC membrane proteins (22µg/ml)
4	PBMC membrane proteins (44µg/ml)

25

The negative control lanes are marked "-E2 CHO"

4.2. Cell surface expression of receptor

30 Employing the protocols described above, various cell types were analysed using FACscan and western blotting for the presence of the 24kd protein putative HCV receptor.

The results are depicted below:

			<u>FACS</u>	<u>W.B.</u>	<u>HV</u>
5	T and B lympho	human	+++	+++	##
	Monocytes	human	+++		##
	HeLa	human	++		##
	Gastric carcinoma	human	++		##
	Hepatoma cells	human	+++	+++	##
10	Myoblastoma	human	+		-
	Fresh liver cells	Green monkeys	-	-	-
	Lymphomonocytes	rabbit	-		-
	Fresh liver cells	rabbit		-	-
	Any cells	mouse	-		-

15

These results demonstrate that the species distribution of the 24kd protein matches that of HCV infection susceptibility.

20 4.3. Effect of enzymes on 24kd protein binding

4.3.1. Flow cytometry

25 The biochemical nature of the cell surface component (receptor) that mediates attachment of E2 CHO envelope protein to Molt 4 cells was investigated. Pretreatment of Molt 4 cells with *V. cholerae* neuraminidase, which has a α -2,3 specificity does not reduce E2 CHO binding.

30 The proteinaceous nature of the receptor was demonstrated when cells pretreated with proteases abolished binding capability of E2 CHO whereas phospholipase treatment of cells did not affect the binding, suggesting that the cellular attachment proteins were not
 35 glycosylphosphatidylinositol anchor linked. The E2 binding site on Molt 4 cells was sensitive to all protease used, which included both serine proteases, such as trypsin, and a thiol protease, such as papain.

The results of proteolytic treatment demonstrated the involvement of membrane proteins in envelope protein binding and were as follows:

5

Treatment	Concentration	Fluorescence intensity
		(% of control)
Control		100
Pronase E	10 µg/ml	36
Pronase E	100 µg/ml	34
Trypsin	100 µg/ml	33
Papain	100 µg/ml	42
Phospholipase C (from <i>Bacillus cereus</i>)	3U/ml	100
Phospholipase C	25U/ml	96
Neuraminidase	50mU/ml	100

Cells (10^6 ml $^{-1}$) were incubated for 60 min at 37°C in RPMI 1640/Hepes medium plus the enzymes indicated above. The cells were centrifuged, resuspended in fresh medium and 30 incubated with E2 CHO protein (3µg/ml). Purified anti E2 CHO monoclonal antibody (1.5 µg/ml) was used as a second step. Purified phycoerythrin-labelled rabbit anti mouse antibody (5 µg/ml) was used as a third step reagent. A total of 5000 cells per sample was evaluated with a FACScan 35 flow cytometer.

Enzymes were used at a concentration that did not affect cell viability as measured by propidium iodine exclusion

during FACS analysis.

Fluorescence was recorded as arbitrary units (channel numbers) on a logarithmic scale and median intensities 5 determined. Data from individual experiments were normalized with respect to the fluorescence of unstained control samples and value are expressed as percentages of the fluorescence intensities in the stained control samples.

10 4.3.2. Western blot on MOLT-4/N-Glycosidase F

Peptide N-Glycosidase F treatment was performed incubating membrane proteins (50 µg) overnight at 37°C in phosphate buffer pH 7,4,25 mM EDTA plus enzyme (50 U/ml) and 15 successively loaded on 12% SDS PAGE.

To show the activity N-Glycosidase F enzyme (PNGase F), as control, gp 120 polypeptide was used in the same experiment (data not shown).

20

The results are shown in Figure 9.

<u>Lane</u>	<u>Description</u>
1	+/ve control
25 2	treated and boiled membrane
3	untreated and boiled membrane
4	treated membrane
5	untreated membrane

30 These results show that treatment of a MOLT 4 membrane preparation with Peptide-N-glycosidase F, which hydrolyzes all N-linked glycans, does not abolish E2 CHO binding.

4.4. Effect of reducing condition on binding

35

A western blot of MOLT-4 and COS-7 membranes, prepared as described above, were electrophoresed in reducing and non reducing conditions to establish the requirement or

otherwise for disulphide bridges in the 24kd protein, by measuring the binding of E2-CHO to the transfer support.

Transfer supports were incubated with E2-CHO recombinant
5 protein as described above.

The results are shown in Figure 10.

	<u>Lane</u>	<u>Description</u>
10	1A	COS-7 membranes in non reducing SDS Laemmli buffer
	2A	MOLT-4 membranes in non reducing SDS Laemmli buffer
15	3A	COS-7 membranes in SDS Laemmli buffer containing 5% β -SH
	4A	MOLT-4 membranes in SDS Laemmli buffer containing 5% β -SH

1B to 4B are negative controls for the corresponding lanes
20 1A to 4A.

5. Optimising Purification

5.1. Immunoprecipitation

25

Membrane Proteins Solubilization

A membrane preparation from 400 million MOLT-4 cells (A2A6 subclone) was treated with 200 μ l of PBS buffer, pH 7.4,
30 containing CHAPS 7.5 mM and the following protease inhibitors in μ l/ml: PMSF 35, aprotinin 2, pepstatin 0.7, leupeptin 0.5. After treatment with the above buffer, the resulting suspension was centrifuged at 100,000 g for 1 hour and the clear supernatant underwent immunoprecipitation
35 experiments. The final protein concentration based on BCA protein assay (Pierce, USA) was 2.7 mg/ml.

Incubation with E2 recombinant envelope protein

200 μ l of membrane protein solution (2.7 mg/ml) in PBS-CHAPS were added to 15 μ l of CHO-produced E2 (Batch P4) solution.

5 The stock concentration of E2-P4 protein was 130 μ l/ml and its final concentration in the protein membrane solution was 9.75 μ g/ml.

The mixture was kept overnight under stirring at 4°C.

10

Incubation with Rabbit anti-E2 antisera

The resulting solution was divided into two aliquots of 100 μ l and each was mixed with 5 μ l of preimmune and

15 postimmune antiserum from a rabbit (R#1) previously immunized with E2 protein. The final dilution of antisera was 1:20. Incubation was performed for 1 hour at 4°C.

Addition of Protein-A Sepharose CL-4B

20

Protein-A Sepharose CL-4B resin (Pharmacia, Sweden) was extensively washed with PBS containing 7.5 mM CHAPS at pH 7.4, and 30 μ l of compact slurry (capacity of matrix is 20 mg of human Ig per ml of slurry) were added to each 100 μ l sample resulting from the step above. Incubation was performed under stirring for 1 hour at 4°C.

The samples were centrifuged to pellet down the resin and the supernatant was removed, mixed with Laemmli-Buffer (without reducing agent) and kept for SDS-PAGE. The resin pellet was washed twice with 500 μ l of PBS-CHAPS (10 min each wash at 4°C) and then the pellet was treated with 50 μ l of Laemmli Buffer containing 5M urea. The resulting supernatant was subjected to SDS-PAGE.

35

SDS-PAGE and Immunoblot

The samples from the steps above, that is, supernatant

containing material not absorbed on Protein-A matrix (SN) and material desorbed from Protein-A matrix (ProtA) from both preimmune and postimmune antisera, were loaded on SDS-PAGE gel in non reducing buffer and without heating. After 5 the run, the gels were electroblotted on nitrocellulose paper in 20% methanol Tris-Glycine buffer and were subjected immunostaining as described above. Incubation with E2 protein was performed overnight using E2 SMC-PC at 1.73 µg/ml in PBS 0.05% Tween 20.1% milk.

10

The samples loaded on SDS-PAGE were:

- A) Supernatant (material not retained by Prot-A) from Preimmune antiserum,
- 15 B) Prot-A desorbed material from PREimmune antiserum,
- C) Supernatant from POSTimmune antiserum, and
- D) Prot-A desorbed material from POSTimmune antiserum

20 Three sets of these samples were loaded on gel, one was stained directly on gel the other two underwent immunostain, one incubated with E2 the other as negative control.

25 The nitrocellulose transferred support was incubated with E2-CHO SMC-PC recombinant protein at 1.73 µg/ml followed by 291A2 hybridoma culture supernatant (containing a monoclonal antibody that recognises epitopes exposed on E2 when bound to its putative receptor), biotinylated polyclonal anti-mouse Ig antibodies and peroxidase labelled Extravidin™ (Sigma Immunochemicals, USA). Chemiluminescent staining 30 obtained with ECL-Luminol (Amersham, GB), exposure 1 minute.

The results are shown in Figure 11.

	<u>Lane</u>	<u>Description</u>
35	1A	molecular weight standard
	2A	empty
	3A	sample incubated with preimmune rabbit serum - supernatant

4A sample incubated with preimmune rabbit serum - Protein-A bound
5A sample incubated with postimmune rabbit serum - supernatant
5 6A sample incubated with postimmune rabbit serum - Protein-A bound

The negative controls employed the nitrocellulose membrane incubated with 291A2 hybridoma culture supernatant followed 10 by biotinylated polyclonal anti-mouse Ig antibodies and peroxidase labelled streptavidin. 1B to 4B correspond to 3A to 6A respectively.

5.2. Ammonium Sulphate Fractionation

15 Membranes were prepared as reported in the membrane preparation protocol from MOLT-4 cells and solubilized in PBS buffer pH 7.4 containing 8 mM CHAPS. The protein concentration estimated on the basis of BCA assay ranges 20 from 1.8 and 2.5 mg/ml.

Solubilized membranes were mixed with an ammonium sulphate (AS) saturated solution in a volume sufficient to obtain 25% saturation of ammonium sulphate (i.e. the final 25 concentration of AS is 25% of the starting saturated solution). The sample was allowed to stand in melting ice for 2 hours and then centrifuged at 15800 g for 30 minutes.

30 The supernatant was mixed with AS saturated solution to a final saturation of 50%. The sample was allowed to stand for 2 hours on melting ice and then filtered on a Spin-X™ centrifuge filter unit (Costar, Cambridge, MA, USA) for 15 minutes at 4°C.

35 The precipitates obtained above were dissolved in suitable buffers and undergo further treatment.

The pellets were redissolved in PBS pH 7.4 containing 10M

urea and underwent Laemmli SDS-PAGE. The volumes of AS fractions were loaded in such a way that the amount of putative receptor should be comparable in different samples.

5 The transfer support was incubated with E2-CHO recombinant protein as described above.

The results are shown in Figure 12 and show that precipitation of p24 occurs in the range of 33 to 50% of 10 saturation.

<u>Lane</u>	<u>Description</u>
1A	Starting membranes
2A	20% AS fraction
15 3A	33% AS fraction
4A	43% AS fraction
5A	50% AS fraction
6A	60% AS fraction

20

5.3. Hydrophobic Interaction Chromatography

1.5 ml of solubilized membranes from MOLT-4 cells (protein concentration 2.5 mg/ml) were pre-fractionated at 25% of 25 saturation of ammonium sulphate and the supernatant from this step was brought to 50% saturation of AS. The precipitate obtained was resuspended in 200 µl of PBS containing ammonium sulphate at 25% of saturation. The undissolved material was pelleted by centrifugation at 15800 30 g for 30 minutes. The supernatant obtained was incubated with 200 µl of Phenyl-Sepharose matrix (Pharmacia, Uppsala, Sweden), previously equilibrated in PBS pH 7.2 containing AS at 25% of saturation, for 2 hours at room temperature.

35 The non retained material was recovered by filtering on a Spin-X™ centrifuge filter units (Costar, USA).

The matrix of Phenyl-Sepharose was washed twice with 100 µl

of PBS, 25% AS saturation and once with 300ml of the same buffer. The matrix was then eluted with PBS pH 7.4 (200 μ l) and then with PBS, pH 7.4 containing 20 MeOH. Finally, the matrix was treated with 40 μ l of non reducing Laemmli buffer.

Samples containing ammonium sulphate (i.e. non retained and wash material) were dialysed against 8M urea in PBS, pH 7.4.

10 All samples underwent SDS-PAGE analysis and Western Blot.

5.4. Acetone precipitation

15 50 μ l of membranes from MOLT-4 cells solubilized in 8 mM CHAPS in PBS, pH 7.4 were mixed with 200 μ l of acetone.

The sample was centrifuged at 15800g for 15 minutes and the supernatant was discarded. The obtained precipitate was dissolved in non reducing Laemmli sample buffer and 20 underwent SDS-PAGE and Western Blot. The transfer supports incubated with E2-CHO recombinant protein as described above.

25 The results of the combined HIC and acetone precipitation experiment are shown in Figure 13.

<u>Lane</u>	<u>Description</u>
1A	Starting membranes (16 μ l total protein content)
2A	material non retained on matrix
3A	wash
4A	material eluted with PBS, pH 7.4
5A	material eluted with PBS, pH 7.4 containing 20% Methanol
6A	material eluted with Laemmli Buffer
7A	membranes solubilized in Triton 1% PBS, pH 7.4 (26 μ g total protein)
8A	acetone precipitate from sample 7A

Samples from 1B to 8B correspond to samples from 1A to 8A

These experiments show that ammonium sulphate precipitated
5 material can be redissolved in suitable conditions and undergo hydrophobic interaction chromatography. The 24kd HCV putative receptor protein binds to Phenyl Sepharose and can be recovered from this matrix.

10 The membrane extract can be precipitated with acetone without loss of binding capacity of HCV putative receptor.

6. Sequencing and cloning

15 6.1. Amino acid sequence

The amino acid sequence of the 24kd protein may be elucidated either by inference from the cloned DNA or by microsequencing of protein prepared by one of the processes
20 described above. Based upon the molecular weight of the protein (and the knowledge that, if glycosylated it is only glycosylated to a small extent) it is expected that the protein will have approximately 210 - 230 amino acids (allowing the average of 110 daltons per amino acid).

25

6.2. DNA sequence cloning and sequencing

The DNA sequence of the 24kd protein may be determined by one of a number of techniques known to the art, such as
30 λgt11 "shotgun" cloning where a DNA library is produced, suitably from a hyperexpressing cell-line (see above) and fragments of DNA were caused to express in prokaryotic or eukaryotic cell, the products being screened using antibodies to the 24kd protein or by binding to recombinant
35 E2-CHO.

Once identified, the DNA encoding the 24kd protein may be used to produce large quantities of the protein which, as a

result of its binding to HCV may prove useful in an assay for HCV infection or for the manufacture of a medicament for treating HCV infection.

- 5 Alternatively, the DNA may be used to prepare transgenic animals bearing the 24kd protein which may then serve as animal models for HCV infection.

It will be understood that the invention is described above
10 by way of example and modifications within the scope and spirit of the invention may be made without the need for undue experiment or the exercise of inventive ingenuity.

References

1. European patent application EP-A-0318216
2. European patent application EP-A-0388232
- 5 3. Choo et al PNAS USA (1991) 88 2451-2455
4. Chien, D.Y. et al PNAS USA (1992) 89 10011-10015
5. Spaete, R.R. et al Virology (1992) 188 819-830
6. Gething et al Nature [needs complete reference]
7. "Flow Cytometry" in Methods of Cell Biology, 1990 Vol. 33 Academic Press San Diego
- 10 8. Morre' D.J. et al., Methods Enzymol. (1994) 228, 448-450
9. Laemmli et al Nature (1970) 27 680

CLAIMS

1. A protein having a molecular weight of about 24kD and capable of specifically binding to a protein of hepatitis C virus, or a functionally equivalent variant or fragment thereof.
2. A protein or a functionally equivalent variant or fragment thereof according to claim 1 which is functionally unglycosylated.
3. A protein or a functionally equivalent variant or fragment thereof according to claim 1 or 2 wherein the protein is a transmembrane protein.
4. A process for the preparation of a protein or a functionally equivalent variant or fragment thereof according to any one of claims 1 to 3 comprising the step of culturing cells exhibiting binding to an HCV protein and purifying from a cell preparation a protein according to any one of claims 1 to 3.
5. A process according to claim 4 wherein the cell preparation is a plasma cell membrane preparation.
6. A process according to claim 4 or 5 wherein the cells are selected and cloned to provide hyperexpression of the protein according to any one of claims 1 to 3.
7. A process according to any one of claims 4 to 6 wherein the cell preparation is subjected to an ammonium sulphate precipitation purification step employing ammonium sulphate at between 33 and 50%
8. A process according to any one of claims 4 to 7 wherein the purification involves at least one step of hydrophobic interaction chromatography.

9. A process according to any one of claims 4 to 8 wherein the process involves at least one step of acetone precipitation

5 10. A process according to any one of claims 4 to 8 wherein comprising the steps of:

10 i) preparing a plasma cell membrane preparation of mammalian cells selected for hyperexpression of the 24kd protein of the invention,

15 ii) subjecting the preparation to ammonium sulphate precipitation at less than 33% saturation and retaining the supernatant,

20 iii) subjecting the supernatant to ammonium sulphate precipitation at between 33 and 50% saturation and retaining the precipitate, and

iv) resuspending the precipitate and subjecting it to hydrophobic interaction chromatography

11. A method for treating an infection of HCV comprising administering to a patient an amount of a protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment thereof effective to reduce the infectivity of the virus.

12. A pharmaceutical composition comprising a protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment thereof, optionally as a pharmaceutically acceptable salt, in combination with a pharmaceutically acceptable carrier.

35 13. A process for preparing a pharmaceutical composition, in which a protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment


thereof is brought into association with a pharmaceutically acceptable carrier.

14. A protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment thereof for use as a pharmaceutical.
5
15. Use of a protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment thereof in the manufacture of a medicament for the treatment of an HCV infection.
10
16. An assay for HCV antibodies in a serum sample comprising the step of allowing competitive binding between antibodies in the sample and a known amount of an HCV protein for binding to a protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment thereof and measuring the amount of the known HCV protein bound
15
17. A diagnostic kit comprising the protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment thereof.
20
18. A method for screening chemical compounds for ability to bind to the region of HCV responsible for binding to a host cell, comprising measuring the binding of a chemical compound to be screened to a protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment thereof.
25
19. A transgenic non-human mammal, carrying a transgene encoding a protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment thereof.
30
20. A process for producing a transgenic animal comprising the step of introducing a DNA encoding a
35

protein according to any one of claims 1 to 3 or a functionally equivalent variant or fragment thereof into the embryo of a non-human mammal, preferably a mouse.

//4

FIG. 1



09/011910

WO 97/09349

PCT/IB96/00943

2/14

FIG.2(A)

MOLT 4





FIG.2(B)

JURKAT



3/14

FIG. 2(C)

K562





FIG. 2(D)

EBV-B



09/011910

WO 97/09349

PCT/IB96/00943

4/14

FIG. 2(E)





FIG. 2(F)



09/011910

WO 97/09349

PCT/IB96/00943

5/14

FIG. 2(G)
ADENOCARCINOMA





FIG. 2(H)
HUH 7



09/011910

WO 97/09349

PCT/IB96/00943

6/14

FIG. 3(A)

PURIFIED RA





FIG. 3(B)

PURIFIED RO



SUBSTITUTE SHEET (RULE 26)

09/011910

PCT/IB96/00943

WO 97/09349

7/14

FIG. 3(C)

CORD BLOOD PURIF. RA





FIG. 3(D)

CORD BLOOD RA PHA STIM.



SUBSTITUTE SHEET (RULE 26)

09/011910

WO 97/09349

PCT/IB96/00943

8/14

FIG. 3(E)

KC3 TCC





FIG. 3(F)

SAG S9 TCC



SUBSTITUTE SHEET (RULE 26)

09/011910

WO 97/09349

PCT/IB96/00943

9/14

E2 CHO (CONF.)




FIG. 4

E2 CHO (CONF.)




FIG. 5

09/011910

PCT/IB96/00943

WO 97/09349

10/14

FIG. 6





FIG. 7



09/011910

PCT/IB96/00943

WO 97/09349

11/14

FIG. 8





FIG. 9



09/011910

WO 97/09349

PCT/IB96/00943

12/14

FIG. 10





FIG. 11




09/01/1910

WO 97/09349

PCT/IB96/00943

13/14

FIG. 12




09/01/1910

PCT/IB96/00943

WO 97/09349

14/14

FIG. 13



DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

BINDING PROTEIN

the specification of which (check one) is attached hereto was filed on
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

=====

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) Number	Country	Priority Claimed Day/Month/Year Filed	Yes	No
9517926.3 PCT/IB96/00943	GB PCT	01 September 1995 30 August 1996	X	X

=====


I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status
		Patented, Pending, Abandoned

=====

I hereby declare that all statements herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Sergio Abrignani

Inventor's signature: 

Date: 3/2/96

Residence: Piazza Fabbrini, 5, Vagliagli, 53010 Castelnuovo Berardenga (SI), ITALY ITX

Citizenship: ITALY

Post Office Address: Same as above

Patent 0336.001